Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib and T-DM1 in HER2-positive Metastatic Solid Tumors with Brain Metastases
NCT05673928Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib, trastuzumab emtansine in metastatic solid tumor, brain metastases, sponsored by University of Texas MD Anderson Cancer Center. Started May 2023; status: recruiting.
02
Drugs
tucatinibtrastuzumab emtansine
03
Conditions
metastatic solid tumorbrain metastases
Beyond the preview
Go deeper on NCT05673928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673928.